ImmunoGen gets FDA breakthrough therapy status for IMGN632 to treat relapsed or refractory BPDCN
ImmunoGen has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its IMGN632 to treat patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN).